MetLife Investment Advisors LLC purchased a new position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 69,125 shares of the biopharmaceutical company’s stock, valued at approximately $8,267,000.
A number of other institutional investors have also recently modified their holdings of ALXN. Amundi Pioneer Asset Management Inc. increased its holdings in shares of Alexion Pharmaceuticals by 1,786.3% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 1,454,498 shares of the biopharmaceutical company’s stock valued at $173,944,000 after acquiring an additional 1,377,388 shares during the period. Investec Asset Management LTD acquired a new position in shares of Alexion Pharmaceuticals in the 4th quarter valued at $84,096,000. Alkeon Capital Management LLC acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter valued at $70,145,000. TIAA CREF Investment Management LLC increased its holdings in shares of Alexion Pharmaceuticals by 12.1% in the 4th quarter. TIAA CREF Investment Management LLC now owns 3,836,919 shares of the biopharmaceutical company’s stock valued at $458,857,000 after acquiring an additional 414,969 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in shares of Alexion Pharmaceuticals by 32.7% in the 3rd quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock valued at $218,647,000 after acquiring an additional 383,713 shares during the period. Institutional investors own 95.34% of the company’s stock.
Alexion Pharmaceuticals stock opened at $117.89 on Thursday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34. The firm has a market cap of $26,650.54, a price-to-earnings ratio of 23.71, a PEG ratio of 1.11 and a beta of 1.13.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The business had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. During the same period in the prior year, the company posted $1.26 EPS. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. research analysts predict that Alexion Pharmaceuticals, Inc. will post 6.12 earnings per share for the current year.
In other news, SVP Heidi L. Wagner sold 698 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $119.35, for a total transaction of $83,306.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Ludwig Hantson sold 13,245 shares of the company’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total transaction of $1,540,525.95. Following the transaction, the chief executive officer now directly owns 131,425 shares in the company, valued at $15,286,041.75. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 31,253 shares of company stock worth $3,656,229. Corporate insiders own 4.35% of the company’s stock.
A number of equities analysts have recently commented on ALXN shares. Robert W. Baird raised shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 target price on the stock in a report on Monday, December 18th. BidaskClub raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 27th. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. UBS cut shares of Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a report on Thursday, January 4th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and issued a $147.00 target price on shares of Alexion Pharmaceuticals in a report on Thursday, January 18th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty-one have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $155.22.
WARNING: This piece was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://ledgergazette.com/2018/03/22/metlife-investment-advisors-llc-invests-8-27-million-in-alexion-pharmaceuticals-inc-alxn-stock.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.